Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.

Inclusion Criteria:

* Cytological or histologically confirmation of pancreatic cancer.
* WHO performance status of 0 or 1
* ASA classification I or II
* Tumor considered locally advanced after diagnostic work-up including CT-imaging and diagnostic laparoscopy.
* No evidence of metastatic disease
* Largest tumor diameter \< 7 cm x 7 cm x 7 cm
* Normal renal function (Creatinine ≥ 30 ml/min).
* Normal liver tests (bilirubin \< 1.5 times normal; ALAT/ASAT \< 5 times normal)
* Normal bone marrow function (WBC \> 3.0 x 10e9/L, platelets \> 100 x 10e9/L and hemoglobin \> 5.6 mmol/l)
* Age \> 18 years and \< 75 years
* Written informed consent

Exclusion Criteria:

* Prior radiotherapy, chemotherapy or resection (bypass surgery allowed).
* Lymph node metastases from primary tumor outside the field of radiation.
* Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence.
* Pregnancy, breast feeding.
* Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.